[go: up one dir, main page]

WO2007008490A3 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer - Google Patents

Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer Download PDF

Info

Publication number
WO2007008490A3
WO2007008490A3 PCT/US2006/025993 US2006025993W WO2007008490A3 WO 2007008490 A3 WO2007008490 A3 WO 2007008490A3 US 2006025993 W US2006025993 W US 2006025993W WO 2007008490 A3 WO2007008490 A3 WO 2007008490A3
Authority
WO
WIPO (PCT)
Prior art keywords
zosuquidar
cytarabine
daunorubicin
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/025993
Other languages
French (fr)
Other versions
WO2007008490A2 (en
Inventor
Branimir Sikic
Daniel Hoth
David Socks
Scott Glenn
John Marcelletti
Michael J Walsh
Pratik S Multani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANISA PHARMACEUTICALS Inc
Original Assignee
KANISA PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/416,832 external-priority patent/US20070010466A1/en
Application filed by KANISA PHARMACEUTICALS Inc filed Critical KANISA PHARMACEUTICALS Inc
Priority to CA002614324A priority Critical patent/CA2614324A1/en
Priority to JP2008520333A priority patent/JP2009501707A/en
Priority to EP06774465A priority patent/EP1898916A4/en
Priority to AU2006269492A priority patent/AU2006269492A1/en
Publication of WO2007008490A2 publication Critical patent/WO2007008490A2/en
Anticipated expiration legal-status Critical
Publication of WO2007008490A3 publication Critical patent/WO2007008490A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating newly diagnosed Acute Myelogenous Leukemia (AML).
PCT/US2006/025993 2005-07-06 2006-06-30 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer Ceased WO2007008490A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002614324A CA2614324A1 (en) 2005-07-06 2006-06-30 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
JP2008520333A JP2009501707A (en) 2005-07-06 2006-06-30 Zoschidar, daunorubicin, and cytarabine for the treatment of cancer
EP06774465A EP1898916A4 (en) 2005-07-06 2006-06-30 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
AU2006269492A AU2006269492A1 (en) 2005-07-06 2006-06-30 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US69693005P 2005-07-06 2005-07-06
US60/696,930 2005-07-06
US11/416,832 2006-05-03
US11/416,832 US20070010466A1 (en) 2005-07-06 2006-05-03 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US11/416,571 2006-05-03
US11/416,829 2006-05-03
US11/416,571 US20070010465A1 (en) 2005-07-06 2006-05-03 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US11/416,829 US20070010478A1 (en) 2005-07-06 2006-05-03 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer

Publications (2)

Publication Number Publication Date
WO2007008490A2 WO2007008490A2 (en) 2007-01-18
WO2007008490A3 true WO2007008490A3 (en) 2008-01-10

Family

ID=37637706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025993 Ceased WO2007008490A2 (en) 2005-07-06 2006-06-30 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer

Country Status (6)

Country Link
EP (1) EP1898916A4 (en)
JP (1) JP2009501707A (en)
KR (1) KR20080034151A (en)
AU (1) AU2006269492A1 (en)
CA (1) CA2614324A1 (en)
WO (1) WO2007008490A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530295A (en) * 2013-09-06 2016-09-29 ヴァンダ ファーマシューティカルズ インコーポレイテッド Treatment of CYR61 and VEGF-mediated conditions
WO2015078929A1 (en) * 2013-11-27 2015-06-04 Oncoethix Sa Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
JP2019525924A (en) * 2016-07-27 2019-09-12 ユニバーシティ オブ バージニア パテント ファウンデーション Combination therapy to treat cancer
WO2023144830A1 (en) 2022-01-30 2023-08-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Zika m protein blockers as anti-zika virus agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269708A1 (en) * 2000-07-18 2002-01-30 Eli Lilly And Company Novel method of use of multidrug resistance modulators

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAKER ET AL.: "MDR1, Chemotherapy, and Chromatin Remodeling", CANCER BIOL. THER., vol. 3, no. 9, September 2004 (2004-09-01), pages 819 - 824, XP008097898 *
GERRARD ET AL.: "Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine", HAEMATOLOGICA, vol. 89, no. 7, July 2004 (2004-07-01), pages 782 - 790, XP002489757 *
HAMADA ET AL.: "Interaction of Imatinib Mesilate with Human P-Glycoprotein", J. PHARMACOL. EXP. THER., vol. 302, no. 2, November 2003 (2003-11-01), pages 824 - 828, XP002404663 *
See also references of EP1898916A4 *
SMITH ET AL.: "Circumvention of P-glycoprotein-mediated Multiple Drug Resistance by Phosphorylation Modulators Is Independent of Protein Kinases", J. BIOL. CHEM., vol. 270, no. 47, 24 November 1995 (1995-11-24), pages 28145 - 28152, XP008097975 *
WALTER ET AL.: "Multidrug resistance protein attenuates gemtuzumab ozogamicininduced cytotoxicty in acute myeloid leukemia cells", BLOOD, vol. 102, no. 4, 15 August 2003 (2003-08-15), pages 1466 - 1473, XP008097901 *

Also Published As

Publication number Publication date
JP2009501707A (en) 2009-01-22
EP1898916A4 (en) 2008-10-15
KR20080034151A (en) 2008-04-18
WO2007008490A2 (en) 2007-01-18
EP1898916A2 (en) 2008-03-19
AU2006269492A1 (en) 2007-01-18
CA2614324A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2009067397A3 (en) Treatment for solid tumors
WO2006015263A3 (en) Lonidamine analogs
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007038868A3 (en) Novel enediyne compound and uses thereof
TNSN07294A1 (en) Treatment of metastasized tumors
EP2301533A8 (en) Wortmannin Analogs and Method of Using Same
DE60228544D1 (en) TRIPTOLID PRODRUGS FOR CANCER THERAPY
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
WO2004080421A3 (en) Improved antitumoral treatments
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2005000204A3 (en) Pancreatic cancer treatment
WO2007008490A3 (en) Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
WO2007126787A3 (en) Reagents and methods for cancer treatment and prevention
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2005079849A3 (en) Compounds for enhanced cancer therapy
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680032176.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2614324

Country of ref document: CA

Ref document number: 2008520333

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/000226

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006774465

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 492/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006269492

Country of ref document: AU

Ref document number: 1020087003227

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008101019

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006269492

Country of ref document: AU

Date of ref document: 20060630

Kind code of ref document: A